<DOC>
	<DOCNO>NCT00573950</DOCNO>
	<brief_summary>Cilostazol antiplatelet agent use reduce symptom intermittent claudication . Cilostazol inhibit phosphodiesterase III ( PDE III ) , cause vasodilator inhibitor platelet aggregation . Recently report beneficial effect cilostazol like vasodilation , lipid metabolism , cytokine production . But clinical study support effect cilostazol . The purpose study evaluate vasodilatory anti-inflammatory effect cilostazol present PWV plasma adipocytokines .</brief_summary>
	<brief_title>Effects Cilostazol Plasma Adipocytokine Arterial Stiffness</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Cilostazol</mesh_term>
	<criteria>Eligible study : 18 year , Gender eligible study : Inclusion Criteria : Type 2 diabetes patient metabolic syndrome criterion AsianPacific ATP III guideline Type 2 diabetes ( least 1 criterion ) 1. fast blood glucose ≥ 126 mg/dL 2. postprandial 2hour glucose ≥ 200 mg/dL 3. random blood glucose ≥ 200 mg/dL typical diabetes symptom Metabolic syndrome : AsianPacific ATP III guideline 1 . Fasting blood glucose ≥ 110 mg/dL , previously diagnose type 2 diabetes 2. systolic and/or diastolic blood pressure ≥130/85 mmHg , treatment previously diagnose hypertension 3 . Triglyceride ≥ 150 mg/dL , Specific treatment lipid abnormality 4 . HDLcholesterol &lt; 40 mg/dL men &lt; 50 mg/dL woman , Specific treatment lipid abnormality 5 . Waist circumference ≥ 90 men ≥ 80 woman Hypertensive patient use ACE inhibitor ARB Hyperlipidemic patient use statin fenofibrate Hepatic dysfunction Chronic alcohol drug abuse Renal dysfunction Heart failure Patients take hormone replace therapy steroid contain drug Patients take drug like anticoagulant ( warfarin ) , antiplatelet agent ( aspirin , ticlopidin ) , thrombolytic agent ( urikinase , alteplase ) , prostaglandine E1 , drug inhibit CYP3A4 CYP2C19 , drug become substrate CYP3A4 Patients have disease influence result study neurologic , digestive neoplastic disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>cilostazol</keyword>
	<keyword>Type 2 Diabetes mellitus</keyword>
	<keyword>Metabolic Syndrome</keyword>
	<keyword>adipocytokines</keyword>
	<keyword>arterial stiffness</keyword>
	<keyword>Pulse wave velocity</keyword>
</DOC>